标题: |
HIV/AIDS患者血脂综合管理中国专家共识 |
title: |
Chinese Expert Consensus on Comprehensive Lipid Management in HIV/AIDS Patients |
版本: |
原创版 |
version: |
Original |
分类: |
专家共识 |
classification: |
Experts consensus |
领域: |
综合 |
field: |
Comprehensive guideline |
国家和地区: |
中国 |
Country and
region:
|
China |
指南使用者: |
感染科、心内科和内分泌科等临床医师 |
Guide users:
|
Clinicians in Infectious Diseases and Cardiovascular Diseases |
证据分级方法: |
GRADE |
Evidence grading
method:
|
GRADE |
制定单位: |
HIV/AIDS患者血脂综合管理中国专家共识专家组 |
Formulating unit: |
Chinese Expert Consensus Panel on Comprehensive Lipid Management in HIV/AIDS Patients |
注册时间: |
2023-03-15 |
Registration time: |
注册编号: |
PREPARE-2023CN163 |
Registration number: |
指南制订的目的: |
近年来,我国新发现的HIV/AIDS患者人数不断增加,主要人群HIV感染风险持续上升。随着HIV/AIDS患者生存期逐渐延长,长期使用抗病毒药物所致代谢异常引发体重增加、血脂异常、糖尿病、代谢综合征等诸多并发症愈发引人关注。动脉粥样硬化性心血管疾病(arteriosclerotic cardiovascular disease, ASCVD)是HIV/AIDS患者最易合并的非艾滋病定义性疾病(non-AIDS-defining disease, NAD),也是非AIDS相关死亡的首要原因,极大地加重艾滋病疾病负担,严重影响HIV/AIDS患者的预期寿命与远期预后。目前,我国尚无针对艾滋病的专家共识指导接受长期ART的HIV/AIDS患者的血脂管理。基于这一现状,我们邀请国内感染病学和心血管领域的专家,结合我国抗病毒治疗实际和前沿基础/临床研究成果,共同编写HIV/AIDS患者血脂综合管理中国专家共识。 |
Purpose of the guideline:
|
In recent years, the number of newly identified HIV/AIDS patients in China has been increasing, and the risk of HIV infection in major populations continues to rise. ASCVD(arteriosclerotic cardiovascular disease) is the most common form of NAD(non-AIDS-defining disease) in HIV/AIDS patients and the leading cause of non-AIDS related death, which greatly increases the burden of AIDS disease and seriously affects the life expectancy and long-term prognosis of HIV/AIDS patients. ASCVD is the most common combination of NAD in HIV/AIDS patients and the leading cause of non-AIDS related deaths. Currently, there is no AIDS-specific expert consensus guiding the lipid management of HIV/AIDS patients receiving long-term ART in China. Based on this situation, we invited experts in the field of infectious diseases and cardiovascular disease in China to compile a Chinese expert consensus on comprehensive lipid management for patients with HIV/AIDS, taking into account the actual antiviral treatment and cutting-edge basic/clinical research results in China. |